Vivacelle Bio had a very successful clinical trial of its phospholipid nanoparticles in patients with severe septic shock who were not responding to standard of care. Vivacelle Bio company statement: The relatively unexplored region between life and death is the focus of our scientific journey and the source of our life saving discoveries. https://lnkd.in/ejD7aFtW
Vivacelle Bio, Inc.
Biotechnology Research
Chicago, Illinois 318 followers
A New Paradigm In Fluid Resuscitation
About us
VIVACELLE BIO, Inc. is a developmental stage biotechnology company developing products utilizing nanoparticle technology. Their first product, VBI-1, a colloid non-blood volume expander appears to be safer and far more effective than the standard treatment for hypovolemia in animal studies and received green light from FDA to start a phase IIa clinical trial in hypovolemia due to blood loss. The immediate other product in the pipeline is VBI-S, targeting hypovolemia due to sepsis/septic shock. Hypovolemia results from inadequate fluid volume in the blood vessels, causes the death of over a one million people globally each year. Major causes for fluid loss are trauma, surgery, shock, sepsis, severe diarrhea and burns. Inadequate circulating volume impairs tissue perfusion and oxygenation leading to cell injury and death. Rapid volume replacement and re-establishment of normal blood pressure are essential for survival. Currently available options of fluid replacements are non-blood volume expanders (colloids and crystalloids), blood products and blood substitutes. They have proven to be impractical and have the potential for significant negative adverse effects. VBI-1, represents a new paradigm in fluid resuscitation, safely restoring blood vessel volume and reversing the effects of hypovolemia. VBI-1 also modulates Nitric Oxide (a potent vasodilator that drops the blood pressure and a precursor to highly highly toxic mediators), reduces reperfusion injury, inhibits the inflammatory response, clears the endotoxin, metabolizes to naturally-occurring components and acts as an energy source. In addition, it can be loaded with readily available oxygen.
- Website
-
http://www.VivacelleBio.com
External link for Vivacelle Bio, Inc.
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Chicago, Illinois
- Type
- Privately Held
- Founded
- 2013
- Specialties
- Bionanotechnology, Micelles, Treatment for hypovolemia, and Biotechnology
Locations
-
Primary
EnterpriseWorks Chicago
2242 W. Harrison St., Suite 201
Chicago, Illinois 60612, US
-
3201 Stellhorn Road
Suite 129 A
Fort Wayne, IN 46815, US
Employees at Vivacelle Bio, Inc.
-
Mukesh Kumar, PhD, RAC
Chief Executive Officer at FDAMap, Brij Strategic Consultations
-
Harven DeShield, PhD, JD, MSc
CEO & Director at Vivacelle Bio, Inc. I Life, Chemical & Pharma. Sciences COO, VP, Business Development, Head, Corporate & IP Strategy & Snr…
-
Cuthbert Simpkins
Chief Innovation Officer and President at Vivacelle Bio, Inc.
-
Cuthbert Simpkins MD
--
Updates
-
Vivacelle Bio had a very successful clinical trial of its phospholipid nanoparticles in patients with severe septic shock who were not responding to standard of care. Vivacelle Bio company statement: The relatively unexplored region between life and death is the focus of our scientific journey and the source of our life saving discoveries. https://lnkd.in/ejD7aFtW
Efficacy and safety of phospholipid nanoparticles (VBI-S) in reversing intractable hypotension in patients with septic shock: a multicentre, open-label, repeated measures, phase 2a clinical pilot trial
thelancet.com
-
Vivacelle Bio had a very successful clinical trial of our phospholipid nanoparticles in patients who had severe septic shock. he study was published in the Lancet's eClinicalmedicine. The company is moving on to phase III. https://lnkd.in/ejD7aFtW
Efficacy and safety of phospholipid nanoparticles (VBI-S) in reversing intractable hypotension in patients with septic shock: a multicentre, open-label, repeated measures, phase 2a clinical pilot trial
thelancet.com
-
https://lnkd.in/dWZmUakc We, the VivacelleBio team proud to present our Ph 2a study results published in The Lancet. #VBI-S #SepticShock #Hypotension #MAPimprovement
Efficacy and safety of phospholipid nanoparticles (VBI-S) in reversing intractable hypotension in patients with septic shock: a multicentre, open-label, repeated measures, phase 2a clinical pilot trial
thelancet.com
-
There we have it. Now we cannot easily say which countries drive on the wrong/right side of the road… Reasonable and enlightening explanation. #OldVSNotSoOld #LeftVSright
The History Behind Driving on the Left or Right Side of the Road
elaireinsurance.com
-
Is it really a name change ?! Change in strategy on the other hand is inevitable for any company as times are changing rapidly. If good things result from it, why not….
Why Novartis is changing the name of its research labs
https://www.statnews.com
-
Biosimilar natalizumab is aproved by FDA.
Novartis comes for a Biogen MS drug with new biosimilar - Boston Business Journal
bizjournals.com